Oscar Health, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Thu, August 6, 2026 at 8:13 PM GMT+3 3 min read

Oscar Health, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Market Dynamics

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved record first-half profitability with $1 billion in net income, driven by disciplined pricing and a scalable technology platform that expanded operating leverage.
Attributed significant MLR improvement to a strong current-year performance and a market reset compared to the prior year, alongside favorable utilization trends.
Leveraged the proprietary 'Oswell' AI agent to guide 1 in 4 members to high-value care sites, resulting in an average savings of $75 per appointment.
Utilized AI-powered medical economics models to identify pharmacy cost outliers early, expecting these capabilities to generate tens of millions in annual savings.
Positioned the individual market as a vital solution for the evolving labor market, specifically targeting gig workers, part-time employees, and early retirees.
Maintained a competitive advantage through a single-platform data architecture, allowing for AI deployment at scale without the integration costs faced by competitors.
Reported that 2026 market morbidity is tracking favorably to pricing assumptions, suggesting the market contraction is less severe than initially anticipated.

Outlook and Strategic Assumptions

Raised full-year 2026 earnings from operations guidance to $500 million - $700 million, reflecting strong first-half momentum and favorable morbidity trends.
Anticipates a rational 2027 pricing environment with rates reflecting CMS program integrity efforts and the potential for market stability or growth.
Expects increasing membership churn in the second half of 2026 as CMS eligibility verification processes accelerate, though revenue guidance remains reaffirmed.
Assumes full-year MLR will land between 81.5% and 82.5%, incorporating an expectation of seasonal utilization increases as members meet deductibles.
Projects continued SG&A efficiency with a full-year ratio of 15.6% to 16.1%, despite planned fourth-quarter investments for 2027 open enrollment.

Operational Risks and Structural Updates

Recognized a $160 million favorable risk adjustment true-up for 2025 in the second quarter following the final CMS report.
Launched 'ICHRAx', an electronic data exchange platform designed to facilitate employer transitions from defined benefit to defined contribution plans.
Noted that while outpatient utilization was slightly elevated in the first half, it remains stable and is offset by favorability in inpatient and pharmacy categories.
Flagged ongoing CMS program integrity reviews regarding member eligibility, noting that the company does not recognize revenue for members anticipated to be disenrolled.

Q&A Session Highlights

Drivers of elevated outpatient utilization and second-half expectations

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management noted that while outpatient costs are slightly elevated, the trend is stable and offset by favorability in professional and pharmacy categories.
Expects MLR to trend higher quarterly in the back half as members burn through deductibles, following historical seasonal patterns.

Impact of AI on labor markets and intermediate growth

Management views AI as a catalyst for shifting workers toward the gig economy and part-time roles rather than causing mass unemployment.
This shift expands the Total Addressable Market (TAM) for Individual Coverage Health Reimbursement Arrangements (ICHRA) among small and mid-market employers.

CMS program integrity efforts and potential membership loss

Management is actively reviewing CMS files regarding unauthorized members and noted that many on the list have had verified contact or claims.
Confirmed that the financial impact of potential disenrollments is already baked into the full-year guidance and risk assumptions.

Sustainability of SG&A improvements and technology leverage

Achieved long-term SG&A targets a year ahead of schedule due to variable cost efficiencies driven by AI and fixed cost leverage.
Indicated further room for margin expansion if top-line growth continues to outpace the underlying cost structure.